YD Bio Ltd (YDES) SEC Filings & Earnings Calls
EquiReason read 11 YD Bio Ltd SEC filings in the last 12 months. Latest: 6-K on 2026-09-01 — YD Bio Ltd filed a 6-K interim report for the period ending June 30, 2026..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 350.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- —
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
11 Aug 20266-KYD Bio launches two nutraceutical products in Taiwan via a physician-partnership model with CDHA and FHI; no financial terms disclosed.open
Risks flagged
Early-stage initiative with no disclosed financial metrics; execution risk and uncertain revenue contribution.
“intends to explore additional opportunities ... capital-light relative to therapeutic and diagnostic programs”
1 May 20266-KYD Bio reports FY2025 net revenue up 17% to $597K but net loss widens to $8.3M from $1.4M; cash $6.0M; R&D spend up 226%; no guidance provided.earningsopen
Figures in the filing · each found in the filing text
| Net Revenue · FY2025 | $596817.00 | +17% y/y |
| Gross Profit · FY2025 | $168000.00 | +8% y/y |
| Net Loss · FY2025 | $8M | +489% y/y |
| Cash and Cash Equivalents · FY2025 | $6M | |
| Research and Development Expenses · FY2025 | $2M | +226% y/y |
Risks flagged
Cash burn rate high relative to cash position; net loss $8.3M vs cash $6.0M.
“Net Loss $8.3M; Cash $6.0M.”
Revenue concentration in top 5 products (41% of total) and reliance on Keytruda sales.
“The top 5 individual products by revenue accounted for 41% of the total revenue during the period.” · word for word
Operating expenses surged 236% with no corresponding revenue growth to offset.
“Total Operating Expenses $5.4M vs $1.6M.”
30 Apr 202620-FAnnual report (20-F) filed by YD Bio Ltd, a pre-revenue biotech company with going concern risk.open
Figures in the filing · each found in the filing text
| Revenue from Novartis · Clinical Testing Drug Supply · FY2025 | $189253.00 | +63% y/y |
| Revenue from Alcon · Clinical Testing Drug Supply · FY2025 | $51209.00 | -69% y/y |
| Capital Expenditures · FY2025 | $1M | -52% y/y |
| Outstanding Ordinary Shares · 2025-12-31 | 70,789,261 | |
| Outstanding Warrants · 2025-12-31 | 15,142,911 | |
| Top Supplier Concentration · FY2025 | 83.7% | |
| Top Customer Concentration · FY2025 | 53.7% |
Risks flagged
Going Concern Risk
“YD Bio incurred recurring losses and negative cash flows from operations for the years ended December 31, 2025 and 2024, and will likely continue to experience significant negative cash flow and operating losses until an adequate revenue base is established. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.” · word for word
Customer Concentration Risk
“YD Bio’s top three corporate customers — Novartis, Zuelling and Alcon — accounted for approximately 53.7% of the company’s total revenue for the year ended December 31, 2025.” · word for word
Supplier Concentration Risk
“For the year ended December 31, 2025, the Company’s top supplier is 3D Global, which accounted for 83.7% of the Company’s purchases.” · word for word
License Dependency Risk
“We are highly dependent on the intellectual property licensed from EG BioMed, pursuant to which we license DNA methylation analysis technology for application in pancreatic cancer and breast cancer (the “EG BioMed License Agreements”).” · word for word
Regulatory Approval Risk
“We have not yet obtained FDA clearance or approval for any of our cancer detection test products.” · word for word
26 Feb 20266-KYD Bio USA entered into Master Strategic Alliance Agreement with YC Biotech to create Taiwan-U.S. Dual-Core regulatory platform for FDA submissions; YD Bio USA becomes exclusive U.S. Agent for YC Biotech's CRO clients in Asia.open
Risks flagged
No financial terms disclosed; partnership may not generate immediate revenue.
“No deal amount or financial terms mentioned in the filing.”
30 Jan 20266-KYD Bio Ltd entered into a binding LOI to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. for NT$839,832,000 (mix of cash and shares), bolstering immunocell therapy capabilities.acquisitionopen
Risks flagged
Transaction completion risk: subject to due diligence, restructuring, and no material adverse change; no definitive agreement yet.
“There can be no assurance that the Parties will enter into definitive agreements or that the Transaction will be completed.” · word for word
Integration risk: combining two distinct platforms (diagnostics and cell therapy) may pose operational challenges.
“Acquisition of SSMC's ADCTA platform and late-stage clinical assets requires integration into YD Bio's existing portfolio.”
16 Jan 20266-KMajority shareholders removed four directors and elected two new ones via written consent; significant board overhaul.open
Risks flagged
Board instability and potential governance risk due to shareholder-driven removal of four directors.
“Removal of four directors via written consent by majority shareholders.”
17 Nov 20256-KResignation of audit committee chair and appointment of new independent director and audit committee chair; also notification of loss of independence of another director.open
Risks flagged
Loss of independent director may indicate governance risk; Nasdaq compliance period triggered.
“Company notified that Ms. Jan Hall no longer qualifies as independent director; 180-day cure period under Nasdaq Listing Rule 5605(c)(4)(B).”
YD Bio Ltd — questions
- What did YD Bio Ltd file recently?
- 11 SEC filings in the last 12 months. Latest: 6-K on 2026-09-01 — YD Bio Ltd filed a 6-K interim report for the period ending June 30, 2026.
Every figure on this page comes from YD Bio Ltd's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.